An innovative cancer drug for cats opens up new possibilities for humans

Researchers at the University of California, Davis, and the University of California, San Francisco, conducted a groundbreaking clinical trial in cats with oral squamous cell carcinoma, a particularly aggressive and difficult-to-treat tumor. They developed an innovative molecule, based on a small fragment of circular DNA, that acts as a “decoy”: it attracts and neutralizes the STAT3 protein, a transcription factor that is hyperactivated in approximately 75% of human cancers. Until now, STAT3 was considered an untargetable molecule. This new approach, based on the use of “trap” DNA that mimics the sequence recognized by STAT3, makes it possible to block its oncogenic action with unprecedented precision. This is a major scientific breakthrough that paves the way for more targeted and potentially less toxic treatments.

Encouraging Results in Cats

Twenty cats with this type of oral cancer participated in the clinical trial. Over the course of one month, they received six intravenous injections of the molecule. The results are promising: in approximately 35% of the cats, the tumor stabilized or shrank, with minimal side effects. One of the cats in the study, named Jak, illustrates the potential of this treatment: diagnosed with a prognosis of just a few weeks, he survived for more than eight months after receiving the experimental therapy. These results offer new hope for cats with cancers that were previously considered virtually incurable.

A treatment that also boosts immunity

Beyond the direct effect on the tumor, researchers observed a positive modulation of the immune system. Analyses conducted on treated cats and mouse models showed an increase in immune cells capable of fighting cancer, as well as a decrease in cells that typically inhibit the immune response. This dual action—blocking tumor growth while reactivating the body’s natural defenses—could significantly enhance the treatment’s effectiveness. Furthermore, the researchers identified distinct biological profiles between cats that responded well to the treatment and those that did not, paving the way for the development of predictive biomarkers. These biomarkers could, in the long term, allow for more precise selection of animals likely to benefit from this therapy.

Promising Prospects in Human Medicine

This innovation illustrates the value of comparative medicine, which draws on the similarities between feline and human cancers. Oral squamous cell carcinomas in cats share many molecular characteristics with cancers of the mouth and throat in humans. The researchers now plan to expand their work to early-phase clinical trials in humans, while continuing research in cats to optimize protocols and explore combination therapies. Ultimately, this approach could benefit both veterinary oncology and human oncology by accelerating the transition from basic discoveries to clinical application.

A Major Breakthrough in the Fight Against Cancer

By effectively targeting a protein long considered “inaccessible” and stimulating the immune response, this treatment marks an important milestone in the development of next-generation cancer therapies. It offers new hope to animal owners whose animals are suffering from serious cancers, while opening up concrete prospects for human patients.

This study also illustrates the growing importance of animal models in medical research and confirms the value of translational medicine: discoveries made in animals help accelerate the development of innovative treatments for all species.